Clinical Trial Update: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study [Phase 2]

View source ↗

Summary

Phase 2 CLO-FAST trial evaluating shorter regimens containing clofazimine and rifapentine for drug-susceptible tuberculosis was terminated, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Clofazimine (clofazimine)
• rifapentine (rifapentine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV, Tuberculosis | Phase 2 | Status: TERMINATED | Results posted: 2025-08-27